Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
Chung, C.W., Dai, H., Fernandez, E., Tinworth, C.P., Churcher, I., Cryan, J., Denyer, J., Harling, J.D., Konopacka, A., Queisser, M.A., Tame, C.J., Watt, G., Jiang, F., Qian, D., Benowitz, A.B.(2020) ACS Chem Biol 15: 2316-2323
- PubMed: 32697072 
- DOI: https://doi.org/10.1021/acschembio.0c00266
- Primary Citation of Related Structures:  
6ZHC - PubMed Abstract: 
The Bcl-2 family of proteins, such as Bcl-xL and Bcl-2, play key roles in cancer cell survival. Structural studies of Bcl-xL formed the foundation for the development of the first Bcl-2 family inhibitors and FDA approved drugs. Recently, Pro teolysis Ta rgeting C himeras (PROTACs) that degrade Bcl-xL have been proposed as a therapeutic modality with the potential to enhance potency and reduce toxicity versus antagonists ...